Combined loss of p21 waf1/cip1 and p27 kip1 enhances tumorigenesis in mice

Laboratory Investigation

Volumn 91, Issue 11, 2011, Pages 1634-1642

  García Fernández, Rosa A ^a   García Palencia, Pilar ^a   Sánchez, María Á ^a   Gil Gómez, Gabriel ^b   Sánchez, Belén ^a   Rollán, Eduardo ^a   Martín Caballero, Juan ^b   Flores, Juana M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Barcelona Biomedical Research Park   (Spain)

Author keywords

animal model; cyclin dependent kinase inhibitor; p21 Waf1 C ip1; p27 Kip1; tumor development

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; DOWN REGULATION; FEMALE; GAMMA RADIATION; HYPOPHYSIS ADENOMA; LIFESPAN; MALE; MOUSE; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION INDUCED NEOPLASM; THYMUS LYMPHOMA; THYROID ADENOMA;

ANIMALS; CASPASE 3; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA PRIMERS; ENDOCRINE GLAND NEOPLASMS; GENOTYPE; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MICE; POLY(ADP-RIBOSE) POLYMERASES; POLYMERASE CHAIN REACTION;

EID: 80155151895     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.133     Document Type: Article

References (45)

1. Sherr CJ, Roberts JM. Cdk inhibitors: positive and negative regulators of G1-phase progression. Gene Dev 1999;13:1501-1512. (Pubitemid 29297917)
2. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;19:817-825. (Pubitemid 23346378)
3. Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816. (Pubitemid 23346377)
4. Deng C, Zhang P, Harper W, et al. Mice lacking p21cip1/waf1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-684.
5. Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell 2007;18:665-679. (Pubitemid 46802385)
6. LaBaer J, Garrett MD, Stevenson LF, et al. New functional activities for the p21 family of Cdk inhibitors. Gene Dev 1997;11:847-862. (Pubitemid 27175292)
7. Wang YA, Elson A, Leder P. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci 1997;94:14590-14595. (Pubitemid 28041418)
8. De la Cueva E, Garc?́a-Cao I, Herranz M, et al. Tumorigenic activity of p21Waf1/Cip1 in thymic lymphoma. Oncogene 2006;25:4128-4132. (Pubitemid 44024876)
9. Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/ Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 2002;179:1-14. (Pubitemid 34195647)
10. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9:400-414.
11. Martin-Caballero J, Flores JM, Garc?́a-Palencia P, et al. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001;61: 6234-6238.
12. Franklin DS, Godfrey VL, O'Brien DA, et al. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 2000;20: 6147-6158. (Pubitemid 30613062)
13. Barboza JA, Liu G, Ju Z, et al. p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci USA 2006;103: 19842-19847. (Pubitemid 46037518)
14. Mart?́n-Caballero J, Flores JM, Garc?́a-Palencia P, et al. Different cooperating effect of p21 or p27 deficiency in combination with INK4a/ARF deletion in mice. Oncogene 2004;28:8231-8237. (Pubitemid 39531834)
15. Shen KC, Heng H, Wang Y, et al. ATM and p21 cooperate to suppress aneuploidy and subsequent tumor development. Cancer Res 2005;65:8747-8753. (Pubitemid 41377363)
16. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74. (Pubitemid 24228301)
17. Besson A, Gurian-West M, Schmidt A, et al. p27Kip1 modulates cell migration through the regulation of RhoA activation. Gene Dev 2004;18:862-876. (Pubitemid 38529656)
18. Nakasu S, Nakajima M, Handa J. Anomalous p27kip1 expression in a subset of malignant gliomas. Brain Tumor Pathol 1999;16:17-21.
19. Sánchez-Beato M, Camacho FI, Mart?́nez-Montero JC, et al. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 1999;94:765-772. (Pubitemid 29323891)
20. Blain WS, Massagué J. Breast cancer banished p27 from nucleus. Nat Med 2002;8:1076-1078. (Pubitemid 35175956)
21. Rosen DG, Yang G, Cai KQ, et al. Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res 2005;11:632-637. (Pubitemid 40116889)
22. Qi CF, Xiang S, Shin MS, et al. Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas. Leuk Res 2006;30:153-163. (Pubitemid 41773335)
23. Fero ML, Rivkin M, Tasch M, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-744.
24. Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;31:707-720.
25. Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996;31:721-732.
26. Geisen C, Karsunky H, Yücel R, et al. Loss of p27(Kip1) cooperates with cyclin E in T-cell lymphomagenesis. Oncogene 2003;22: 1724-1729.
27. Sotillo R, Renner O, Dubus P, et al. Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res 2005;65: 3846-3852. (Pubitemid 40616365)
28. Martins CP, Berns A. Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J 2002;21:3739-3748. (Pubitemid 34787047)
29. Jackson RJ, Coppola D, Cantor A, et al. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene 2003;21:8486-8497. (Pubitemid 36054889)
30. Damo LA, Snyder PW, Franklin DS. Tumorigenesis in p27/p53- and p18/p53-double-null mice: functional collaboration between the pRb and p53 pathways. Mol Carcinog 2005;42:109-120.
31. Quereda V, Martinalbo J, Dubus P, et al. Genetic cooperation between p21(Cip1) and INK4 inhibitors in cellular senescence and tumor suppression. Oncogene 2007;26:7665-7674. (Pubitemid 350224221)
32. Besson A, Hwang HC, Cicero S, et al. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Gene Dev 2007;15:1731-1746. (Pubitemid 47076473)
33. Choudhury AR, Ju Z, Djojosubroto MW, et al. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet 2007;39:99-105. (Pubitemid 46026508)
34. Mohr U. International Classification of Rodent Tumors. The Mouse. Springer. WHO International Agency for Research on Cancer, 2001, pp 4
35. Baldassarre G, Belletti B, Bruni P, et al. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Invest 1999;104:865-874. (Pubitemid 29536336)
36. Fedele M, Palmieri D, Chiappetta G, et al. Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice. Endocr Relat Cancer 2009;16:483-490.
37. Zirbes TK, Baldus SE, Moenig SP, et al. Prognostic impact of p21/waf1/ cip1 in colorectal cancer. Int J Cancer 2000;89:14-18. (Pubitemid 30078744)
38. Mitomi H, Mori A, Kanazawa H, et al. Venous invasion and down-regulation of p21(WAF1/CIP1) are associated with metastasis in colorectal carcinomas. Hepatogastroenterology 2005;52: 1421-1426. (Pubitemid 41391006)
39. Winters ZE, Hunt NC, Bradburn MJ, et al. Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer: association with prognosis. Eur J Cancer 2001;37:2405-2412. (Pubitemid 33097478)
40. Ping B, He X, Xia W, et al. Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers. Int J Oncol 2006;29:1103-1110.
41. Shiraki K, Wagayama H. Cytoplasmic p21(WAF1/CIP1) expression in human hepatocellular carcinomas. Liver Int 2006;26:1018-1019. (Pubitemid 44323422)
42. Lloyd RV, Erickson LA, Jin L, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313-323. (Pubitemid 29094081)
43. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183:10-17. (Pubitemid 30130220)
44. Philipp-Staheli J, Payne SR, Kemp CJ. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 2001;10:148-168. (Pubitemid 32989089)
45. Berton S, Belletti B, Wolf K, et al. The tumor suppressor functions of p27(kip1) include control of the mesenchymal/amoeboid transition. Mol Cell Biol 2009;29:5031-5045.